Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib with R-CHOP and MTX/Thiotepa in CNS-involved DLBCL
NCT06901999Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Primary endpoint: Complete Response at 24 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
orelabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06901999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06901999.